Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Goglitazone 15 - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Goglitazone 15

Approved

STANDARD

Goglitazone 15

Umedica Laboratories Pvt. Ltd🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 27ad4389f347308a
Company: Umedica Laboratories Pvt. Ltd
Type: Standard

Approval Details

Approval Id: 27ad4389f347308a
Drug Approval Philippines Name: Goglitazone 15
Product Name: Goglitazone 15
Registration Number: DRP-1183-03
Brand Name: Goglitazone 15
Generic Name: Pioglitazone (as hydrochloride)
Dosage Form: Tablet
Dosage Strength: 15 mg
Manufacturer: Umedica Laboratories Pvt. Ltd
Importer: Suhitas Pharmaceuticals Inc
Distributor: Applied Pharmaceutical Distribution Inc
Issuance Date: 24 April 2024
Expiry Date: 16 December 2028
Pharmacologic Category: Blood Glucose Lowering Drug (Thiazolidinedione)
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

27ad4389f347308a

Type

Standard

Back to Philippines FDA Approvals